Ketamine for PTSD: Which Type Works Best?

How Does Ketamine Work for PTSD?

Ketamine has been FDA-approved as an anesthetic since 1970 and listed on the WHO List of Essential Medicines since 1985,¹ and its use for PTSD is off-label prescribing by licensed clinicians. Ketamine targets brain circuits involved in fear processing and trauma response, which is why researchers have studied it as a treatment for PTSD over the past decade.

The medication temporarily modulates neural communication by interacting with the NMDA receptor. Modulating this receptor creates a surge of glutamate, which stimulates downstream neuroplasticity. Specifically, it increases brain-derived neurotrophic factor (BDNF) and synaptic connectivity in prefrontal and limbic circuits.² These brain regions are directly involved in fear extinction and trauma processing.

Traditional SSRIs work differently, targeting serotonin reuptake pathways with a typical onset of four to six weeks. Published ketamine trials have shown rapid symptom reduction within 24 hours of a single dose,³ with more durable change developing over a defined course of sessions.

The Forms of Ketamine Therapy Studied for PTSD

Ketamine therapies generally fall into two categories: racemic ketamine and esketamine. Racemic ketamine is the original molecule containing both R- and S-enantiomers, while esketamine contains only the S-enantiomer and is marketed as Spravato. Providers deliver these medications via different routes and in different settings.

Bioavailability, onset time, duration of effects, and patient access all depend on the route of administration. Each route involves distinct trade-offs regarding clinical setting requirements and the evidence base for PTSD in particular. Choosing the best type of ketamine therapy depends on the strength of the evidence base for that route, the program's protocol design, post-session integration support, and the patient's ability to complete the course.

Bioavailability is a pharmacokinetic measure of how much of an administered dose reaches systemic circulation; it does not predict PTSD outcomes.⁴ Published evidence indicates that protocol design (dose count, integration, setting) is the stronger predictor of durable response.

Intravenous (IV) Ketamine

Intravenous ketamine is a clinic-administered treatment. Providers typically deliver 0.5 mg/kg over approximately 40 minutes. With nearly 100 percent bioavailability, IV delivery achieves the highest absorption of any route.

Researchers have studied this route the most overall. Without re-dosing, a single infusion's benefits typically wane within one to two weeks.⁹ You must complete an in-clinic visit for each session, with on-site monitoring throughout the experience.

Intranasal Esketamine (Spravato)

Spravato is an S-enantiomer nasal spray. The FDA approved it for treatment-resistant depression in 2019 and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in 2020. It also received approval as a monotherapy for TRD in January 2025.⁵

You must take the medication under REMS supervision in a certified healthcare setting. Staff will monitor you for at least two hours post-dose. PTSD-specific evidence for esketamine is mostly limited to a single pilot study; the route has not yet been tested in phase 2 or phase 3 PTSD trials.

Intramuscular (IM) Ketamine

Intramuscular ketamine involves a single injection into muscle tissue at a clinic. The pharmacokinetics are similar to IV administration. It features a slightly slower onset and slightly lower peak plasma levels.

A licensed clinician must administer this route in a clinic setting. There is limited PTSD-specific evidence for IM ketamine. Most data for this route comes from anesthesia and emergency psychiatry contexts rather than trauma care.

Oral and Sublingual (SL) Ketamine

Sublingual ketamine is delivered as a lozenge or rapid-dissolve tablet held under the tongue or between the cheek and gum. It has lower bioavailability than IV administration, absorbing at approximately 25 to 30 percent.

Sublingual delivery is highly sustainable for multi-session courses because sessions are completed at home under telehealth supervision. Mindbloom is one of the first at-home ketamine therapy companies to publish outcomes for sublingual ketamine, with two peer-reviewed depression studies in the Journal of Affective Disorders^6,7 and the 2026 PTSD preprint⁸ representing the largest published at-home dataset for this condition. Sublingual delivery serves as the foundation for most supervised at-home ketamine therapy programs.

What the Research Says About PTSD Outcomes

Clinical evidence demonstrates meaningful symptom reduction across several ketamine routes, with multi-session protocols producing the strongest durability signals in published research.

The trials below measure results using standard psychiatric instruments like the CAPS-5 and PCL-5. Multi-session protocols paired with structured integration have produced the strongest durability signals in published randomized controlled trials. Single-dose designs show rapid but transient effects, and one large multi-site IV trial failed its primary endpoint. Protocol design shapes results alongside the molecule itself.

IV Ketamine for PTSD

Several key trials have evaluated IV ketamine for PTSD.

• Feder 2014: A proof-of-concept crossover trial (N=41) compared a single infusion of ketamine against midazolam. The study showed rapid PTSD symptom reduction at 24 hours, with effects that were transient relative to multi-session protocols.³
• Feder 2021: Participants received six infusions over two weeks. The trial demonstrated a CAPS-5 reduction of −11.88 compared to the control group, with a large effect size (d = 1.13).⁹
• Albott 2018: An open-label study of 15 veterans used six infusions. In this group, 80 percent achieved PTSD remission.¹⁰
• Abdallah 2022: A multi-site trial of 158 veterans and active duty service members tested two IV doses (0.2 and 0.5 mg/kg). The trial failed to meet its primary endpoint at both doses.¹¹

The six-infusion Feder 2021 trial showed a large effect size (d=1.13), and the open-label Albott 2018 trial reported 80% PTSD remission among veterans completing six infusions. The largest multi-site IV trial (Abdallah 2022, n=158) failed its primary endpoint at both tested doses, underscoring that dose count, protocol design, and patient population shape outcomes alongside the molecule itself.

Intranasal Esketamine for PTSD

Esketamine is FDA-approved for treatment-resistant depression and for MDD with acute suicidal ideation, but not for PTSD. In a 2024 pilot case series of three patients with treatment-resistant PTSD, Rohde and colleagues combined nasal ketamine (0.5 mg/kg weekly) with trauma-focused psychotherapy and observed clinically relevant reductions in CAPS-5 scores.¹²

Oral and Sublingual Ketamine for PTSD

Oral and sublingual routes have been studied through several distinct approaches.

• Hartberg 2018: A retrospective study of oral ketamine augmentation in 37 patients with treatment-resistant depression (15 with primary PTSD) reported a 65% reduction in psychiatric admissions and a 70% reduction in inpatient days, with no tolerance observed.¹³
• Swain et al. 2026 preprint: The largest published dataset of at-home ketamine therapy for PTSD, with 374 adults completing a six-session course; 92.2% reported symptom improvement, with a mean PCL-5 reduction of 44.6% (d=1.44).⁸

What Pooled Analyses Show

Recent meta-analyses have evaluated the broader evidence base for trauma treatment.

• Sicignano and colleagues (2024): A systematic review with meta-analyses across published ketamine-for-PTSD trials reported pooled reductions of −10.63 on the CAPS and −6.13 on the PCL.¹⁴
• Borgogna and colleagues (2024): A systematic review and meta-analysis of six PTSD RCTs reported a pooled effect size of Hedges' g = 0.27 (n = 221), with the authors noting that bias and heterogeneity across studies limited the strength of the pooled estimate.²⁵

Pooled effect sizes are smaller than those reported in individual six-session trials such as Feder 2021, reflecting the heterogeneity of dose count, protocol design, and patient populations across the RCT base. Multi-session protocols paired with integration support have produced the most consistent durability signals.

Five Factors That Determine Which Type of Ketamine Therapy Fits

The best ketamine for PTSD is not a single molecule or route but the combination of delivery method, setting, session count, post-session processing, and access that you can actually complete. Each of the factors below plays a critical role in adherence and overall response. For PTSD in particular, setting and integration deserve outsized weight because trauma symptoms directly interfere with adherence.

Setting Is Particularly Important for PTSD

Care setting is a critical variable for trauma survivors. The DSM-5 diagnostic criteria for PTSD include Criterion C (avoidance), which involves persistent avoidance of trauma-related external reminders.¹⁶ A standard clinic visit sequence requires leaving home and sitting in unfamiliar waiting rooms. You must lie in a supine position while a stranger administers a dissociative agent, then return home while still in the post-session period.

Additionally, Criterion E (hyperarousal) involves an exaggerated startle response and hypervigilance in unfamiliar environments. These factors contribute to notable dropout rates in PTSD psychotherapy trials; a systematic review across 55 studies of cognitive-behavioral and EMDR treatments reported dropout rates ranging widely up to 54 percent, with nonresponse rates exceeding 50 percent on at least some measures in many studies.¹⁷ The Abdallah 2022 multi-site trial, which used an eight-infusion clinic protocol and failed its primary endpoint at both doses,¹¹ has not been replicated under conditions that account for these PTSD-specific barriers.

At-home ketamine therapy functions as part of the clinical intervention, not just a convenience feature. A familiar, controlled environment may reduce avoidance barriers and support completion of the full session course.

Single Dose vs. a Full Course

Single-infusion studies, such as Feder 2014, show rapid but transient effects. Trials with the strongest durability signals, including Feder 2021 and Albott 2018, used six sessions. Six sessions have become the published standard across the most-cited PTSD trials, not a proprietary invention. Whether ketamine can reduce PTSD symptoms after one dose is not in dispute. The real question is whether those changes last without a defined course.

Integration and Psychotherapeutic Support

Integration is the guided process of making sense of and applying insights from ketamine sessions to daily life. Examples include the TIMBER method (mindfulness-based trauma-focused integration, paired with IV ketamine which showed a mean sustained response of approximately 34 days versus 16 days in the placebo-plus-TIMBER arm.¹⁸ Which ketamine modality you choose matters less than whether the program includes preparation and integration. Setting and follow-through are linked, as a patient who drops out at session two due to avoidance never reaches the processing phase.

Durability and Re-Dosing Strategy

IV maintenance typically requires returning to a clinic every two to four weeks indefinitely, presenting a different access calculus than completing a defined at-home course. PTSD patients face specific avoidance barriers to repeated clinic visits. What matters most is sustainability: can you maintain the schedule long enough to achieve and sustain a response?

Cost and Insurance Coverage

Treatment costs vary significantly by modality.

• IV ketamine: Approximately $400 to $800 per infusion, typically not covered by insurance for PTSD.
• Spravato: Insurance may cover this for TRD, but off-label PTSD use is generally not covered.
• At-home sublingual: Lower per-session cost, and comprehensive programs often offer bundled pricing.

What matters most is whether you can finish the full course. A less expensive per-session option that you complete is clinically more valuable than a higher-bioavailability option abandoned at session three.

At-Home Ketamine-Assisted Therapy for PTSD: What Our Clients Experienced

Protocol-driven at-home ketamine-assisted therapy pairs sublingual or subcutaneous ketamine with clinical oversight. The framework includes preparation, guided sessions with a required peer treatment monitor, and post-session integration, addressing the setting and adherence factors described above. If the experience feels unfamiliar, preparation materials and your peer treatment monitor can help you navigate it.

In a 2026 preprint study (Swain, Carter, Vando et al.) conducted on Mindbloom clients using the Mindbloom care protocol, participants demonstrated substantial symptom reduction.⁸

• Headline: 92.2% of clients with PTSD reported symptom improvement.
• Response: 79.7% met response criteria (a 10-point or greater PCL-5 reduction).
• Remission: 60.7% reached remission (PCL-5 score below 33).
• Sample: The study analyzed 374 completers, showing a mean PCL-5 reduction from 51.1 to 28.3 (44.6% reduction) with a large effect size (d = 1.44).
• Session-by-session progression: Response rates grew steadily, reaching 62.2% at session 2, 73.8% at session 4, and 79.7% at session 6.
• Suicidal ideation sub-cohort (n = 58): Of clients who reported suicidal ideation at baseline, 85.2% reported improvement and 75.9% reported complete resolution by session 6.
• Depression and anxiety secondaries: Participants also saw a 51.2% reduction in PHQ-9 scores and a 50.6% reduction in GAD-7 scores.
• Safety: Side effects occurred in 4.3% of sessions, while adverse events occurred in fewer than 0.1%. Individual results may vary.

Mindbloom has facilitated over 800,000 supervised sessions. Mindbloom has published two peer-reviewed studies in the Journal of Affective Disorders (Hull et al. 2022, Mathai et al. 2024) alongside the Mindbloom 2026 preprint.^6,7,8

Ketamine Therapy Alternatives for PTSD

PTSD treatment includes several evidence-based options beyond ketamine. SSRIs (sertraline, paroxetine) are the only FDA-approved pharmacotherapy class for PTSD, with a typical onset of four to six weeks.¹⁹ Trauma-focused psychotherapies — Prolonged Exposure, Cognitive Processing Therapy, and EMDR — are recommended in VA/DoD and APA guidelines.²⁰ Ketamine therapy may be considered as part of an integrated approach alongside or after these treatments.

What This Means for Choosing Treatment

The published evidence points to five factors that consistently shape outcomes in ketamine therapy for PTSD: a setting that doesn't aggravate avoidance and hyperarousal symptoms, a multi-session course rather than a single dose, structured integration support that helps changes hold, a sustainable durability and re-dosing strategy, and a cost-and-access profile compatible with course completion.

For PTSD specifically, at-home ketamine is an option that aligns with all five. The home setting avoids the clinic dynamics that contribute to PTSD-specific dropout. The six-session course matches the published standard set by Feder 2021 and Albott 2018. Telehealth-supervised integration support is built into the program structure. Re-dosing happens in the same sustainable setting rather than requiring ongoing clinic visits. Per-session cost is compatible with completing the full course.

The Mindbloom 2026 preprint is the largest published dataset of at-home ketamine therapy for PTSD, with 374 adults reporting 92.2% symptom improvement and 60.7% remission after a six-session course.⁸

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.